Review



anti pole2 antibodies  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Proteintech anti pole2 antibodies
    <t>POLE2</t> expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.
    Anti Pole2 Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pmc10869977-70-4-7?v=Proteintech
    Average 94 stars, based on 17 article reviews
    anti pole2 antibodies - by Bioz Stars, 2026-08
    94/100 stars

    Images

    1) Product Images from "Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance"

    Article Title: Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance

    Journal: Journal of Cancer

    doi: 10.7150/jca.93023

    POLE2 expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.
    Figure Legend Snippet: POLE2 expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.

    Techniques Used: Expressing, Immunohistochemistry, Comparison

    The effects of POLE2 knockdown on the BLCA cell stemness, proliferation, invasion and migration. (A) The relationship between the POLE2 expression and RNA stemness score (RNAss) in the BLCA. (B) POLE2 expression in the T24 cells transfected with POLE2-short hairpin RNAs (POLE2-shRNAs, including POLE2-shRNA1 and POLE2-shRNA2). (C-F) Effects of POLE2 knockdown on (C) T24 cell stemness assessed by the clonogenic assay, (D) T24 cell growth determined by the CCK-8 assay, (E) T24 cell migration distance after 48 hours transfection determined by the scratch assay, and (F) the T24 cell invasion capability. (G) Effects of POLE2 knockdown on cisplatin chemotherapy resistance. **, p <0.01.
    Figure Legend Snippet: The effects of POLE2 knockdown on the BLCA cell stemness, proliferation, invasion and migration. (A) The relationship between the POLE2 expression and RNA stemness score (RNAss) in the BLCA. (B) POLE2 expression in the T24 cells transfected with POLE2-short hairpin RNAs (POLE2-shRNAs, including POLE2-shRNA1 and POLE2-shRNA2). (C-F) Effects of POLE2 knockdown on (C) T24 cell stemness assessed by the clonogenic assay, (D) T24 cell growth determined by the CCK-8 assay, (E) T24 cell migration distance after 48 hours transfection determined by the scratch assay, and (F) the T24 cell invasion capability. (G) Effects of POLE2 knockdown on cisplatin chemotherapy resistance. **, p <0.01.

    Techniques Used: Knockdown, Migration, Expressing, Transfection, Clonogenic Assay, CCK-8 Assay, Wound Healing Assay



    Similar Products

    pole2 antibodies  (Bioss)
    93
    Bioss pole2 antibodies
    Pole2 Antibodies, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pm37733085-36-2-5?v=Bioss
    Average 93 stars, based on 1 article reviews
    pole2 antibodies - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    anti pole2  (Thermo Fisher)
    86
    Thermo Fisher anti pole2
    Anti Pole2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pm39155507-45-20-23?v=Thermo+Fisher
    Average 86 stars, based on 1 article reviews
    anti pole2 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    anti-pole2  (Thermo Fisher)
    90
    Thermo Fisher anti-pole2
    Anti Pole2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pm39155507-70-6-9?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    anti-pole2 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    anti pole2 antibodies  (Proteintech)
    94
    Proteintech anti pole2 antibodies
    <t>POLE2</t> expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.
    Anti Pole2 Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pmc10869977-70-4-7?v=Proteintech
    Average 94 stars, based on 1 article reviews
    anti pole2 antibodies - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    anti pole2  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti pole2
    <t>POLE2</t> expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.
    Anti Pole2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pm38070189-18-55-57?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    anti pole2 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    antibody anti pole2  (Biorbyt)
    96
    Biorbyt antibody anti pole2
    <t>POLE2</t> expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.
    Antibody Anti Pole2, supplied by Biorbyt, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pm37097331-42-22-27?v=Biorbyt
    Average 96 stars, based on 1 article reviews
    antibody anti pole2 - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    rabbit anti pole2  (Atlas Antibodies)
    92
    Atlas Antibodies rabbit anti pole2
    <t>POLE2</t> expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.
    Rabbit Anti Pole2, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pole2+antibodies/pm36608667-395-64-67?v=Atlas+Antibodies
    Average 92 stars, based on 1 article reviews
    rabbit anti pole2 - by Bioz Stars, 2026-08
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    POLE2 expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.

    Journal: Journal of Cancer

    Article Title: Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance

    doi: 10.7150/jca.93023

    Figure Lengend Snippet: POLE2 expression in the BLCA and its relationship with overall survival. (A&B) Random forest displaying the most important proliferation essential gene (PEG) — POLE2 among the 10 prognostic PEGs. (C-G) Comparisons of POLE2 expression between the BLCA and normal tissues from the datasets (C) GSE13507, (D) GSE37851, (E) GSE40335, (F) GSE52519 and (G) GSE65635. (H) Overall survival difference in BLCA patients with high- and low-POLE2 expression from the GSE13507 dataset. (I&J) Representative immunohistochemistry (IHC) images of POLE2 protein in (I) the BLCA tissues and (J) paired normal urothelial tissues. (K) Histogram of the IHC score revealing markedly higher protein expression of POLE2 in BLCA tissues than in normal tissues. (L) An enhanced protein level of POLE2 in the muscle-invasive BLCA compared to the non-muscle invasive BLCA suggested by the IHC assay. (M) Comparison of POLE2 protein levels between the high-grade non-muscle invasive BLCA and the low-grade non-muscle invasive using the IHC assay. (N) Comparison of POLE2 protein levels between the high-grade muscle invasive BLCA and the low-grade muscle invasive using the IHC assay. *, p <0.05; **, p <0.01; ***, p <0.001.

    Article Snippet: Slides were incubated with anti-POLE2 antibodies (21146-1-AP, Proteintech, Wuhan, China, diluted 1:400) and then assessed by two pathologists.

    Techniques: Expressing, Immunohistochemistry, Comparison

    The effects of POLE2 knockdown on the BLCA cell stemness, proliferation, invasion and migration. (A) The relationship between the POLE2 expression and RNA stemness score (RNAss) in the BLCA. (B) POLE2 expression in the T24 cells transfected with POLE2-short hairpin RNAs (POLE2-shRNAs, including POLE2-shRNA1 and POLE2-shRNA2). (C-F) Effects of POLE2 knockdown on (C) T24 cell stemness assessed by the clonogenic assay, (D) T24 cell growth determined by the CCK-8 assay, (E) T24 cell migration distance after 48 hours transfection determined by the scratch assay, and (F) the T24 cell invasion capability. (G) Effects of POLE2 knockdown on cisplatin chemotherapy resistance. **, p <0.01.

    Journal: Journal of Cancer

    Article Title: Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance

    doi: 10.7150/jca.93023

    Figure Lengend Snippet: The effects of POLE2 knockdown on the BLCA cell stemness, proliferation, invasion and migration. (A) The relationship between the POLE2 expression and RNA stemness score (RNAss) in the BLCA. (B) POLE2 expression in the T24 cells transfected with POLE2-short hairpin RNAs (POLE2-shRNAs, including POLE2-shRNA1 and POLE2-shRNA2). (C-F) Effects of POLE2 knockdown on (C) T24 cell stemness assessed by the clonogenic assay, (D) T24 cell growth determined by the CCK-8 assay, (E) T24 cell migration distance after 48 hours transfection determined by the scratch assay, and (F) the T24 cell invasion capability. (G) Effects of POLE2 knockdown on cisplatin chemotherapy resistance. **, p <0.01.

    Article Snippet: Slides were incubated with anti-POLE2 antibodies (21146-1-AP, Proteintech, Wuhan, China, diluted 1:400) and then assessed by two pathologists.

    Techniques: Knockdown, Migration, Expressing, Transfection, Clonogenic Assay, CCK-8 Assay, Wound Healing Assay